BrightGene Bio-Medical Technology Co., Ltd. Is founded in 2001, The company is a research driven and technology platform-based enterprise, engages in international competition of the whole industry chain of chemical drugs, and has formed continuous profit model covering the whole industry chain including “starting materials-intermediates with high technical difficulty-distinctive APIs-drug products”.
BrightGene has its innovation pipeline including antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); high-end generic drugs mainly include: generic drugs which are difficult to synthesize, semi-synthetic fermentation products, biosimilars and special drug delivery systems (DDS) such as nanoemulsions.
Aim at regulated market, BrightGene has cGMP compliance factories, and has got approval from USFDA, EU, PMDA, KFDA and CFDA.
BrightGene has exceptional R&D capability and robust project execution. Combining high productivity and cost-effective resources, along with unmatched regulatory and technical know-how, BrightGene is uniquely positioned to compete in the global pharmaceutical industry, particularly the fast growing specialty pharmaceutical sector.
|Earnings Per Share||0.21||0.14||0.06|
|R&D expenditure as a % of operating revenue||23.59%||25.51%||26.67%|
|Total Owners' Equity||770||446||220|
|Net Cash Flows-Operating||64||36||30|
|Net Cash Flows-Investing||-212||-81||-37|
|Net Cash Flows-Financing||250||110||12|
|Name||No. of Shares Held (mn)||% of Shares Held|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.